130 related articles for article (PubMed ID: 26842429)
1. A practical divergence measure for survival distributions that can be estimated from Kaplan-Meier curves.
Cox TF; Czanner G
Stat Med; 2016 Jun; 35(14):2406-21. PubMed ID: 26842429
[TBL] [Abstract][Full Text] [Related]
2. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.
Péron J; Roy P; Ozenne B; Roche L; Buyse M
JAMA Oncol; 2016 Jul; 2(7):901-5. PubMed ID: 27124210
[TBL] [Abstract][Full Text] [Related]
3. Estimation of exposure distribution adjusting for association between exposure level and detection limit.
Yang Y; Shelton BJ; Tucker TT; Li L; Kryscio R; Chen L
Stat Med; 2017 Aug; 36(18):2935-2946. PubMed ID: 28513091
[TBL] [Abstract][Full Text] [Related]
4. A group sequential test for survival trials: an alternative to rank-based procedures.
Li Z
Biometrics; 1999 Mar; 55(1):277-83. PubMed ID: 11318168
[TBL] [Abstract][Full Text] [Related]
5. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
[TBL] [Abstract][Full Text] [Related]
6. A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves.
Uno H; Tian L; Claggett B; Wei LJ
Stat Med; 2015 Dec; 34(28):3680-95. PubMed ID: 26194988
[TBL] [Abstract][Full Text] [Related]
7. Assessment of gastric cancer survival: using an artificial hierarchical neural network.
Amiri Z; Mohammad K; Mahmoudi M; Zeraati H; Fotouhi A
Pak J Biol Sci; 2008 Apr; 11(8):1076-84. PubMed ID: 18819544
[TBL] [Abstract][Full Text] [Related]
8. Comparison of survival distributions in clinical trials: A practical guidance.
Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
[TBL] [Abstract][Full Text] [Related]
9. Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.
Díaz I; Colantuoni E; Hanley DF; Rosenblum M
Lifetime Data Anal; 2019 Jul; 25(3):439-468. PubMed ID: 29492746
[TBL] [Abstract][Full Text] [Related]
10. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
11. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
13. Estimation of a decreasing hazard of patients with acute coronary syndrome.
van Geloven N; Martin I; Damman P; de Winter RJ; Tijssen JG; Lopuhaä HP
Stat Med; 2013 Mar; 32(7):1223-38. PubMed ID: 22829475
[TBL] [Abstract][Full Text] [Related]
14. Regression models for the restricted residual mean life for right-censored and left-truncated data.
Cortese G; Holmboe SA; Scheike TH
Stat Med; 2017 May; 36(11):1803-1822. PubMed ID: 28106926
[TBL] [Abstract][Full Text] [Related]
15. Ball divergence for the equality test of crossing survival curves.
You N; He X; Dai H; Wang X
Stat Med; 2023 Dec; 42(29):5353-5368. PubMed ID: 37752757
[TBL] [Abstract][Full Text] [Related]
16. Median tests for censored survival data; a contingency table approach.
Tang S; Jeong JH
Biometrics; 2012 Sep; 68(3):983-9. PubMed ID: 23189327
[TBL] [Abstract][Full Text] [Related]
17. Designing therapeutic cancer vaccine trials with delayed treatment effect.
Xu Z; Zhen B; Park Y; Zhu B
Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
[TBL] [Abstract][Full Text] [Related]
18. Comparison of methods for estimating the attributable risk in the context of survival analysis.
Gassama M; Bénichou J; Dartois L; Thiébaut AC
BMC Med Res Methodol; 2017 Jan; 17(1):10. PubMed ID: 28114895
[TBL] [Abstract][Full Text] [Related]
19. Estimating efficacy in trials with selective crossover.
Brentnall AR; Sasieni P; Cuzick J
Stat Med; 2017 Jul; 36(15):2333-2346. PubMed ID: 28295486
[TBL] [Abstract][Full Text] [Related]
20. Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications.
Thorén FB; Anderson H; Strannegård Ö
Cancer Immunol Immunother; 2013 Oct; 62(10):1547-51. PubMed ID: 23979447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
